TOVX (STOCKS)
Theriva Biologics, Inc.
$0.252400
+0.021700 (+9.41%)
Prev close: $0.230700
Company Information
- Exchange
- XASE
- Sector
- Health Technology
- Industry
- Pharmaceuticals: Major
- CEO
- Steven A. Shallcross
- Asset Type
- stocks
- Website
- Visit
Fundamentals
- Market Cap
- $11.97M
- Employees
- 22
- P/E (TTM)
- -0.06
- P/B (TTM)
- 0.54
- Dividend Yield
- —
Technical Indicators
- SMA 10
- —
- SMA 20
- —
- SMA 50
- —
- EMA 9
- —
- EMA 21
- —
- RSI
- —
- MACD State
- —
Recent News
No recent news found for this ticker.
Financial Statements
| Revenues | $0.00 |
| Nonoperating Income/Loss | $312.00K |
| Operating Expenses | $24.05M |
| Research and Development | $8.60M |
| Other Operating Expenses | $15.45M |
| Operating Income/Loss | -$24.05M |
| Income/Loss From Continuing Operations After Tax | -$23.74M |
| Income/Loss From Continuing Operations Before Tax | -$23.74M |
| Net Income/Loss | -$23.74M |
| Net Income/Loss Attributable To Noncontrolling Interest | $1.51M |
| Net Income/Loss Attributable To Parent | -$25.25M |
| Net Income/Loss Available To Common Stockholders, Basic | -$25.25M |
| Participating Securities, Distributed And Undistributed Earnings/Loss, Basic | $0.00 |
| Preferred Stock Dividends And Other Adjustments | $0.00 |
| Basic Earnings Per Share | -$2.08 |
| Diluted Earnings Per Share | -$2.08 |
| Basic Average Shares | 12,140,697 |
| Diluted Average Shares | 12,140,697 |
| Assets | $38.24M |
| Current Assets | $17.47M |
| Noncurrent Assets | $20.77M |
| Fixed Assets | $222.00K |
| Intangible Assets | $19.62M |
| Other Non-current Assets | $931.00K |
| Liabilities | $22.86M |
| Current Liabilities | $10.01M |
| Accounts Payable | $1.01M |
| Wages | $443.00K |
| Other Current Liabilities | $8.56M |
| Noncurrent Liabilities | $12.84M |
| Long-term Debt | $1.67M |
| Other Non-current Liabilities | $11.17M |
| Equity | $15.38M |
| Equity Attributable To Noncontrolling Interest | $0.00 |
| Equity Attributable To Parent | $15.38M |
| Liabilities And Equity | $38.24M |
| Net Cash Flow From Operating Activities | -$16.67M |
| Net Cash Flow From Operating Activities, Continuing | -$16.67M |
| Net Cash Flow From Investing Activities | -$35.00K |
| Net Cash Flow From Investing Activities, Continuing | -$35.00K |
| Net Cash Flow From Financing Activities | $18.19M |
| Net Cash Flow From Financing Activities, Continuing | $18.19M |
| Exchange Gains/Losses | -$92.00K |
| Net Cash Flow | $1.40M |
| Net Cash Flow, Continuing | $1.49M |
| Comprehensive Income/Loss | -$21.81M |
| Comprehensive Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Comprehensive Income/Loss Attributable To Parent | -$21.81M |
| Other Comprehensive Income/Loss | $1.93M |